Figure 2.

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma. (A) Intention-to-treat progression-free survival (ITT PFS). (B) Intention-to-treat progression-free survival 2 (ITT PFS-2). (C) Intention-to-treat overall survival (ITT OS). (Note that PFS-2 was calculated from the date of enrollment to the date of second relapse/progression or death or the date the patient was last known to be in remission.)